Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.42 |
| ▸ | ADH1C | P00326 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 1/20 | 0.42 |
| ▸ | ADH4 | P08319 | 1/20 | 0.42 |
| ▸ | ADH7 | P40394 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690910 | 1.00 | TSHR (0.42) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL5459351 | 1.00 | TSHR (0.42) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL7923014 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL8411738 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL7615090 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL9579563 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL4662691 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL19252728 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL8958561 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL11445208 | 0.95 | ADH1B (0.47) | TSHRADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214263-A1 | BIODEGRADABLE ADHESIVE COMPOSITION | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) | 2023-07-26 | — | — | EP | disclosed |
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2008319-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-0602478-B1 | Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives | HOFFMANN LA ROCHE (CH) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | TSHR 4574/4885ADH1B 1065/4885ADH1C 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.